Alex M. Stuart-Lovell

Alex’s experience includes advising:

• Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, in its US$187 million Series A financing, led by Frazier Life Sciences, with participation from Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital, and EDB
• Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, on its US$180 million Series A financing
• A healthcare services company in its US$178 million Series E financing
• A telecommunications technology company in its US$40 million Series 7 financing and its earlier US$35 million Series 7A financing
• Endeavor Biomedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, in its US$132.5 million Series C financing, led by AyurMaya, an affiliate of Matrix Capital Management, with participation from Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, and Woodline Partners
• Mirador Therapeutics, Inc., which aims to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases, in its US$400 million financing, led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount and participation from Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments
• Mainstay Medical Holdings plc in its US$125 million equity financing transaction
• CG Oncology, an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, in its US$105 million Series F financing, co-led by Foresite Capital and TCGX, with participation from new investors Avidity Partners, BFG Partners, and Janus Henderson Investors and certain existing investors; and earlier CG Oncology’s US$120 million Series E financing, co-led by ORI Capital, Longitude Capital, and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group, and Senora Capital
• A biotechnology company in its US$100 million Series C financing
• A biotherapeutics company in its US$95 million Series B financing
• An educational technology company in its US$30 million Series A financing, as well as its earlier Series Seed financing